Ventas, Inc. $VTR Position Reduced by Andra AP fonden

Andra AP fonden cut its holdings in shares of Ventas, Inc. (NYSE:VTR) by 50.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 170,400 shares of the real estate investment trust’s stock after selling 173,600 shares during the period. Andra AP fonden’s holdings in Ventas were worth $11,926,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Integrated Advisors Network LLC boosted its stake in shares of Ventas by 8.0% during the 3rd quarter. Integrated Advisors Network LLC now owns 6,251 shares of the real estate investment trust’s stock valued at $438,000 after buying an additional 463 shares during the period. DNB Asset Management AS lifted its position in shares of Ventas by 5.1% during the 3rd quarter. DNB Asset Management AS now owns 89,941 shares of the real estate investment trust’s stock worth $6,295,000 after buying an additional 4,346 shares during the period. Choreo LLC raised its position in Ventas by 9.6% in the 3rd quarter. Choreo LLC now owns 8,825 shares of the real estate investment trust’s stock valued at $622,000 after purchasing an additional 775 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Ventas by 7.3% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,253,875 shares of the real estate investment trust’s stock valued at $87,759,000 after acquiring an additional 84,841 shares during the last quarter. Finally, US Bancorp DE boosted its holdings in Ventas by 1.0% during the third quarter. US Bancorp DE now owns 23,602 shares of the real estate investment trust’s stock worth $1,652,000 after buying an additional 227 shares during the last quarter. 94.18% of the stock is owned by institutional investors and hedge funds.

Ventas Trading Down 0.1%

Shares of Ventas stock opened at $86.38 on Friday. The company has a current ratio of 0.67, a quick ratio of 0.67 and a debt-to-equity ratio of 1.03. The company has a market capitalization of $41.03 billion, a P/E ratio of 159.96, a price-to-earnings-growth ratio of 2.12 and a beta of 0.77. Ventas, Inc. has a 12-month low of $60.15 and a 12-month high of $87.87. The stock has a fifty day simple moving average of $80.00 and a 200 day simple moving average of $75.08.

Ventas (NYSE:VTR) last announced its earnings results on Thursday, February 5th. The real estate investment trust reported $0.15 earnings per share for the quarter, missing analysts’ consensus estimates of $0.89 by ($0.74). The business had revenue of ($1,229.71) million during the quarter, compared to analysts’ expectations of $1.53 billion. Ventas had a return on equity of 2.09% and a net margin of 4.31%.Ventas’s quarterly revenue was up 21.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.81 EPS. Ventas has set its FY 2026 guidance at 3.780-3.880 EPS. On average, sell-side analysts anticipate that Ventas, Inc. will post 3.4 earnings per share for the current fiscal year.

Ventas Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 16th. Shareholders of record on Tuesday, March 31st will be given a $0.52 dividend. This is an increase from Ventas’s previous quarterly dividend of $0.48. This represents a $2.08 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, March 31st. Ventas’s dividend payout ratio (DPR) is 355.56%.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $93.00 target price on shares of Ventas in a research note on Monday, February 9th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $100.00 price target on shares of Ventas in a research report on Monday, February 9th. UBS Group reaffirmed a “neutral” rating and issued a $85.00 price objective on shares of Ventas in a research report on Monday, February 9th. Citigroup increased their price target on shares of Ventas from $88.00 to $96.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Finally, Argus set a $88.00 target price on Ventas in a report on Tuesday, February 10th. Thirteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.87.

Insider Buying and Selling

In related news, CFO Robert F. Probst sold 29,930 shares of the business’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $77.25, for a total value of $2,312,092.50. Following the sale, the chief financial officer directly owned 138,434 shares in the company, valued at approximately $10,694,026.50. The trade was a 17.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Carey S. Roberts sold 35,532 shares of Ventas stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $85.00, for a total transaction of $3,020,220.00. Following the completion of the transaction, the executive vice president owned 72,755 shares of the company’s stock, valued at $6,184,175. This represents a 32.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 86,106 shares of company stock valued at $6,931,397. 0.80% of the stock is owned by insiders.

Ventas Profile

Ventas, Inc (NYSE: VTR) is a real estate investment trust (REIT) that specializes in healthcare-related real estate. The company acquires, owns and manages a diversified portfolio of properties serving the healthcare continuum, including senior housing communities, skilled nursing facilities, medical office buildings, life science and research centers, and other properties leased to healthcare providers and operators. Ventas generates revenue through long-term leases, property management and selective development activities focused on meeting the real estate needs of the healthcare sector.

Ventas’ business model combines property ownership with active asset management and capital markets activity.